A 0 1 0 1 O
subject 2 9 2 9 O
's 9 11 9 11 O
transition 12 22 12 22 O
into 23 27 23 27 O
rollover 28 36 28 36 O
study 37 42 37 42 O
â‰¥ 43 44 43 44 O
45 45 47 45 47 B-lower_bound
days 48 52 48 52 I-lower_bound
after 53 58 53 58 O
End 59 62 59 62 O
of 63 65 63 65 O
the 66 69 66 69 O
Study 70 75 70 75 O
visit 76 81 76 81 O
of 82 84 82 84 O
the 85 88 85 88 O
parent 89 95 89 95 O
oral 96 100 96 100 O
azacitidine 101 112 101 112 O
study 113 118 113 118 O

Females 0 7 119 126 B-gender
of 8 10 127 129 O
childbearing 11 23 130 142 O
potential 24 33 143 152 O
( 34 35 153 154 O
FCBP 35 39 154 158 O
) 39 40 158 159 O
may 41 44 160 163 O
participate 45 56 164 175 O

Have 0 4 176 180 O
two 5 8 181 184 O
negative 9 17 185 193 B-pregnancy
pregnancy 18 27 194 203 I-pregnancy
tests 28 33 204 209 O
as 34 36 210 212 O
verified 37 45 213 221 O
by 46 48 222 224 O
the 49 52 225 228 O
Investigator 53 65 229 241 O
prior 66 71 242 247 O
to 72 74 248 250 O
starting 75 83 251 259 O
study 84 89 260 265 O
therapy 90 97 266 273 B-treatment

Male 0 4 274 278 B-gender

Practice 0 8 279 287 O
true 9 13 288 292 O
abstinence 14 24 293 303 O
( 25 26 304 305 O
which 26 31 305 310 O
must 32 36 311 315 O
be 37 39 316 318 O
reviewed 40 48 319 327 O
on 49 51 328 330 O
a 52 53 331 332 O
monthly 54 61 333 340 O
basis 62 67 341 346 O
) 67 68 346 347 O
or 69 71 348 350 O
agree 72 77 351 356 B-contraception_consent
to 78 80 357 359 I-contraception_consent
use 81 84 360 363 I-contraception_consent
a 85 86 364 365 I-contraception_consent
condom 87 93 366 372 I-contraception_consent
during 94 100 373 379 I-contraception_consent
sexual 101 107 380 386 I-contraception_consent
contact 108 115 387 394 I-contraception_consent
with 116 120 395 399 O
a 121 122 400 401 O
pregnant 123 131 402 410 B-pregnancy
female 132 138 411 417 B-gender
or 139 141 418 420 O
a 142 143 421 422 O
female 144 150 423 429 O
of 151 153 430 432 O
childbearing 154 166 433 445 O
potential 167 176 446 455 O
while 177 182 456 461 O
participating 183 196 462 475 O
in 197 199 476 478 O
the 200 203 479 482 O
study 204 209 483 488 O
, 209 210 488 489 O
during 211 217 490 496 O
dose 218 222 497 501 O
interruptions 223 236 502 515 O
and 237 240 516 519 O
for 241 244 520 523 O
at 245 247 524 526 O
least 248 253 527 532 O
3 254 255 533 534 B-lower_bound
months 256 262 535 541 I-lower_bound

Pregnant 0 8 542 550 B-pregnancy

Prior 0 5 551 556 B-treatment
chemotherapy 6 18 557 569 I-treatment
( 19 20 570 571 O
including 20 29 571 580 O
injectable 30 40 581 591 O
azacitidine 41 52 592 603 B-treatment
) 52 53 603 604 O
or 54 56 605 607 O
radiotherapy 57 69 608 620 B-treatment

She 0 3 621 624 O
must 4 8 625 629 O
agree 9 14 630 635 O
to 15 17 636 638 O
ongoing 18 25 639 646 O
pregnancy 26 35 647 656 B-pregnancy
testing 36 43 657 664 O
during 44 50 665 671 O
the 51 54 672 675 O
course 55 61 676 682 O
of 62 64 683 685 O
the 65 68 686 689 O
study 69 74 690 695 O
, 74 75 695 696 O
and 76 79 697 700 O
after 80 85 701 706 O
end 86 89 707 710 O
of 90 92 711 713 O
study 93 98 714 719 O
treatment 99 108 720 729 B-treatment
. 108 109 729 730 O
This 110 114 731 735 O
applies 115 122 736 743 O
even 123 127 744 748 O
if 128 130 749 751 O
the 131 134 752 755 O
subject 135 142 756 763 O
practices 143 152 764 773 O
true 153 157 774 778 O
abstinence 158 168 779 789 O
from 169 173 790 794 O
heterosexual 174 186 795 807 O
contact 187 194 808 815 O

Subjects 0 8 816 824 O
have 9 13 825 829 O
met 14 17 830 833 O
one 18 21 834 837 O
or 22 24 838 840 O
more 25 29 841 845 O
criteria 30 38 846 854 O
for 39 42 855 858 O
discontinuation 43 58 859 874 O
as 59 61 875 877 O
stipulated 62 72 878 888 O
in 73 75 889 891 O
the 76 79 892 895 O
parent 80 86 896 902 O
oral 87 91 903 907 B-treatment
azacitidine 92 103 908 919 I-treatment
study 104 109 920 925 I-treatment

Subjects 0 8 926 934 O
received 9 17 935 943 O
oral 18 22 944 948 B-treatment
azacitidine 23 34 949 960 I-treatment
in 35 37 961 963 O
combination 38 49 964 975 O
with 50 54 976 980 O
another 55 62 981 988 O
compound 63 71 989 997 O
during 72 78 998 1004 O
a 79 80 1005 1006 O
parent 81 87 1007 1013 O
oral 88 92 1014 1018 O
azacitidine 93 104 1019 1030 O
study 105 110 1031 1036 O
( 111 112 1037 1038 O
Subjects 112 120 1038 1046 O
form 121 125 1047 1051 O
multi 126 131 1052 1057 O
- 131 132 1057 1058 O
arm 132 135 1058 1061 O
parent 136 142 1062 1068 O
oral 143 147 1069 1073 O
azacitidine 148 159 1074 1085 O
studies 160 167 1086 1093 O
will 168 172 1094 1098 O
be 173 175 1099 1101 O
allowed 176 183 1102 1109 O
to 184 186 1110 1112 O
enroll 187 193 1113 1119 O
into 194 198 1120 1124 O
the 199 202 1125 1128 O
rollover 203 211 1129 1137 O
study 212 217 1138 1143 O
, 217 218 1143 1144 O
if 219 221 1145 1147 O
the 222 225 1148 1151 O
subject 226 233 1152 1159 O
is 234 236 1160 1162 O
receiving 237 246 1163 1172 O
single 247 253 1173 1179 B-treatment
- 253 254 1179 1180 I-treatment
agent 254 259 1180 1185 I-treatment
oral 260 264 1186 1190 I-treatment
azacitidine 265 276 1191 1202 I-treatment
at 277 279 1203 1205 O
the 280 283 1206 1209 O
time 284 288 1210 1214 O
of 289 291 1215 1217 O
transition 292 302 1218 1228 O
into 303 307 1229 1233 O
the 308 311 1234 1237 O
rollover 312 320 1238 1246 O
study 321 326 1247 1252 O
) 326 327 1252 1253 O

able 0 4 1254 1258 O
to 5 7 1259 1261 O
comply 8 14 1262 1268 O
with 15 19 1269 1273 O
, 19 20 1273 1274 O
effective 21 30 1275 1284 O
contraception 31 44 1285 1298 O
without 45 52 1299 1306 O
interruption 53 65 1307 1319 O
, 65 66 1319 1320 O
28 67 69 1321 1323 B-upper_bound
days 70 74 1324 1328 I-upper_bound
prior 75 80 1329 1334 I-upper_bound
to 81 83 1335 1337 O
starting 84 92 1338 1346 O
investigational 93 108 1347 1362 O
product 109 116 1363 1370 O
, 116 117 1370 1371 O
during 118 124 1372 1378 O
the 125 128 1379 1382 O
study 129 134 1383 1388 O
therapy 135 142 1389 1396 O
( 143 144 1397 1398 O
including 144 153 1398 1407 O
dose 154 158 1408 1412 O
interruptions 159 172 1413 1426 O
) 172 173 1426 1427 O
, 173 174 1427 1428 O
and 175 178 1429 1432 O
for 179 182 1433 1436 O
3 183 184 1437 1438 B-lower_bound
months 185 191 1439 1445 I-lower_bound
, 191 192 1445 1446 O
or 193 195 1447 1449 O
longer 196 202 1450 1456 O
if 203 205 1457 1459 O
required 206 214 1460 1468 O
by 215 217 1469 1471 O
local 218 223 1472 1477 O
regulations 224 235 1478 1489 O
, 235 236 1489 1490 O
after 237 242 1491 1496 O
discontinuation 243 258 1497 1512 O
of 259 261 1513 1515 O
study 262 267 1516 1521 O
therapy 268 275 1522 1529 O

any 0 3 1530 1533 O
investigational 4 19 1534 1549 O
agent 20 25 1550 1555 O
after 26 31 1556 1561 O
the 32 35 1562 1565 O
last 36 40 1566 1570 O
dose 41 45 1571 1575 O
of 46 48 1576 1578 O
oral 49 53 1579 1583 B-treatment
azacitidine 54 65 1584 1595 I-treatment
administered 66 78 1596 1608 O
as 79 81 1609 1611 O
part 82 86 1612 1616 O
of 87 89 1617 1619 O
the 90 93 1620 1623 O
parent 94 100 1624 1630 O
oral 101 105 1631 1635 O
azacitidine 106 117 1636 1647 O
study 118 123 1648 1653 O

continues 0 9 1654 1663 O
to 10 12 1664 1666 O
fulfill 13 20 1667 1674 O
the 21 24 1675 1678 O
eligibility 25 36 1679 1690 O
criteria 37 45 1691 1699 O
in 46 48 1700 1702 O
one 49 52 1703 1706 O
of 53 55 1707 1709 O
the 56 59 1710 1713 O
parent 60 66 1714 1720 O
oral 67 71 1721 1725 O
azacitidine 72 83 1726 1737 B-treatment
clinical 84 92 1738 1746 O
trials 93 99 1747 1753 O

lactating 0 9 1754 1763 O
females 10 17 1764 1771 B-gender

received 0 8 1772 1780 O
oral 9 13 1781 1785 B-treatment
azacitidine 14 25 1786 1797 I-treatment

subject 0 7 1798 1805 O
is 8 10 1806 1808 O
tolerating 11 21 1809 1819 O
treatment 22 31 1820 1829 B-treatment
with 32 36 1830 1834 O
oral 37 41 1835 1839 B-treatment
azacitidine 42 53 1840 1851 I-treatment
monotherapy 54 65 1852 1863 I-treatment
and 66 69 1864 1867 O
continued 70 79 1868 1877 O
oral 80 84 1878 1882 B-treatment
azacitidine 85 96 1883 1894 I-treatment
treatment 97 106 1895 1904 I-treatment

